Latest news with #EMA
Korea Herald
4 hours ago
- Business
- Korea Herald
SIEW 2025 Registration Opens: Envisioning Energy Tomorrow, Building Systems Today
SINGAPORE, Aug. 1, 2025 /PRNewswire/ -- Registration is now open for the 18th Singapore International Energy Week (SIEW), happening from 27 to 31 October in Singapore. Organised by the Energy Market Authority (EMA), SIEW 2025 will explore the theme " Envisioning Energy Tomorrow, Building Systems Today", highlighting the urgent need to develop secure, sustainable, and affordable energy systems for the future. 2. SIEW 2025 will bring together key industry leaders including: Governments and International Organisations Regulators and Utilities Industry 3. Flagship events at SIEW 2025 include: I. SIEW Summit: Plenary sessions addressing energy resilience, the role of AI, grid integration, natural gas markets, and financing for infrastructure. II. Singapore-IEA Forum: Explores AI's role in smarter, more resilient energy systems and Asia's energy landscape. III. Fifth Singapore- IRENA High-Level Forum: Focuses on regional connectivity and renewable energy investments. IV. The Energy Insights, TechTable, and Thinktank Roundtables will spotlight innovations like small modular reactors, biomethane, and AI-powered low-carbon infrastructure. V. : Hosted by SP Group, CEPSI will examine regional power sector collaboration and system modernisation across Asia Pacific. VI. SG60@SIEW Energy Showcase: Marks Singapore's 60-year energy journey, spotlighting policy innovations and technologies shaping its future to 2065. 4. Held alongside SIEW 2025, partner events will spotlight evolving energy solutions in Asia: I. Asia Clean Energy Summit II. Asia Gas Markets Conference: Role of gas, hydrogen and carbon capture in the energy mix III. : Low-carbon tech and digitalisation in industrial energy transformation 5. Register at to enjoy early bird rates and bundled discounts.
Yahoo
4 hours ago
- Business
- Yahoo
SIEW 2025 Registration Opens: Envisioning Energy Tomorrow, Building Systems Today
SINGAPORE, July 31, 2025 /PRNewswire/ -- Registration is now open for the 18th Singapore International Energy Week (SIEW), happening from 27 to 31 October in Singapore. Organised by the Energy Market Authority (EMA), SIEW 2025 will explore the theme "Envisioning Energy Tomorrow, Building Systems Today", highlighting the urgent need to develop secure, sustainable, and affordable energy systems for the future. 2. SIEW 2025 will bring together key industry leaders including: Governments and International Organisations H.E. Dr Saleh Ali Hamed Al Kharabsheh, Minister of Energy and Mineral Resources, Hashemite Kingdom of Jordan H.E. Eddy Soeparno, People's Consultative Assembly Vice Speaker, Republic of Indonesia Clare McLaughlin, Australia's Governor to the International Energy Agency, and Head of Division, Energy Performance and Security, Australia Dr Fatih Birol, Executive Director, International Energy Agency Francesco La Camera, Director-General, International Renewable Energy Agency Xin Bao'an, Chairman, Global Energy Interconnection Development and Cooperation Organisation Dr Sama Bilbao y León, Director General, World Nuclear Association Dato' Ir. Ts. Razib Dawood, Executive Director, ASEAN Centre for Energy Regulators and Utilities Judy Chang, Commissioner, United States Federal Energy Regulatory Commission Siti Safinah binti Salleh, Chief Executive Officer, Energy Commission, Malaysia Mark McAllister, Chairman, Office of Gas and Electricity Markets, United Kingdom Datuk Ir. Megat Jalaluddin bin Megat Hassan, Chief Executive Officer, Tenaga Nasional Berhad, Malaysia Industry Andy Piepel, Vice President R&D, Electrical Markets Division, 3M Dr Owen Chen, Chief Technology Officer & Vice President, Concord New Energy Group Lim Wee Seng, Group Head of Sustainability, Energy, Renewables & Infrastructure, Project Finance and Strategic Advisory, Institutional Banking Group, DBS Bank Dominic Genetti, Senior Vice President, Carbon Capture and Storage, ExxonMobil Low Carbon Solutions Pablo Koziner, Chief Commercial & Operations Officer, GE Vernova Peter Wong, Executive Director and Managing Director, Hong Kong and China Gas Company Takao Tsukui, President and CEO, Mitsubishi Power Leong Wei Hung, Chief Executive Officer, Singapore LNG Corporation Thorbjörn Fors, Group Senior Vice President and Managing Director of Asia Pacific, Siemens Energy 3. Flagship events at SIEW 2025 include: I. SIEW Summit: Plenary sessions addressing energy resilience, the role of AI, grid integration, natural gas markets, and financing for infrastructure. II. Singapore-IEA Forum: Explores AI's role in smarter, more resilient energy systems and Asia's energy landscape. III. Fifth Singapore- IRENA High-Level Forum: Focuses on regional connectivity and renewable energy investments. IV. The Energy Insights, TechTable, and Thinktank Roundtables will spotlight innovations like small modular reactors, biomethane, and AI-powered low-carbon infrastructure. V. 25th Conference of the Electric Power Supply Industry (CEPSI): Hosted by SP Group, CEPSI will examine regional power sector collaboration and system modernisation across Asia Pacific. VI. SG60@SIEW Energy Showcase: Marks Singapore's 60-year energy journey, spotlighting policy innovations and technologies shaping its future to 2065. 4. Held alongside SIEW 2025, partner events will spotlight evolving energy solutions in Asia: I. Asia Clean Energy Summit: Clean energy innovations from the private sector II. Asia Gas Markets Conference: Role of gas, hydrogen and carbon capture in the energy mix III. Asian Downstream Summit (ADS) | Asian Refining Technology Conference (ARTC) | Ammonia & Carbon Capture Asia (ACCA): Low-carbon tech and digitalisation in industrial energy transformation 5. Register at to enjoy early bird rates and bundled discounts. About the Singapore International Energy Week SIEW is an official trademarked event by the EMA. It is an annual platform for energy professionals, policymakers and commentators to discuss and share best practices and solutions within the global energy space. View original content to download multimedia: SOURCE Energy Market Authority
Business Wire
20 hours ago
- Business
- Business Wire
BeOne Medicines Receives PRIME Designation from the European Medicines Agency for BGB-16673 in Waldenstrom's Macroglobulinemia
SAN CARLOS, Calif.--(BUSINESS WIRE)-- BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Medicines Agency (EMA) has granted PRIority MEdicines (PRIME) designation to the Company's investigational Bruton's tyrosine kinase (BTK) degrader, BGB-16673, for the treatment of patients with Waldenstrom's macroglobulinemia (WM) previously treated with a BTK inhibitor. 'This is the Company's first PRIME designation, marking a milestone for BeOne and providing early and enhanced interaction with the EMA as we advance BGB-16673,' said Julie Lepin, Senior Vice President, Chief Regulatory Affairs Officer at BeOne. 'PRIME allows us to align early with the EMA on key evidence requirements and potentially accelerate our path to marketing authorization of BGB-16673 for patients with relapsed or refractory Waldenstrom's macroglobulinemia.' In addition to the PRIME designation, the EMA's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion on the EU Orphan Drug Designation (ODD) application for BGB-16673 in WM. A final decision is anticipated in the coming weeks. The U.S. Food and Drug Administration (FDA) also granted Fast Track Designation to BGB-16673 for the treatment of adult patients with relapsed or refractory (R/R) chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL), and adult patients with R/R mantle cell lymphoma (MCL). The EMA's CHMP granted PRIME designation to BGB-16673 based on data demonstrating its novel mechanism and anti-tumor activity in B-cell malignancies. The CHMP recognized the limited treatment options available for WM patients post-BTK inhibitor therapy and acknowledged the strong biological rationale and promising clinical data for BGB-16673 in this setting, thereby demonstrating the potential to address the unmet medical need. The PRIME initiative, launched by the EMA in 2016, provides early, proactive, and enhanced regulatory support to developers of promising medicines. It is designed to optimize development plans and accelerate evaluation, helping innovative therapies reach patients with unmet medical needs faster. About BGB-16673 BGB-16673 is an orally available Bruton's tyrosine kinase (BTK) targeting protein degrader from BeOne's chimeric degradation activation compound (CDAC) platform. BGB-16673 is designed to promote the degradation, or breakdown, of both wild-type and mutant forms of BTK, including those that commonly result in resistance to BTK inhibitors in patients who experience progressive disease. BGB-16673 is the most advanced BTK protein degrader in the clinic, with an extensive global clinical development program. About BeOne Medicines BeOne Medicines is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. With a growing global team of more than 11,000 colleagues spanning six continents, the Company is committed to radically improving access to medicines for far more patients who need them. To learn more about BeOne, please visit and follow us on LinkedIn, X, Facebook and Instagram. Forward-Looking Statement This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding BeOne's advancement of, and anticipated clinical development, regulatory milestones and commercialization of BGB-16673; the potential of BGB-16673 to significantly address the unmet medical need; and BeOne's plans, commitments, aspirations, and goals under the heading 'About BeOne.' Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeOne's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing, and progress of clinical trials and marketing approval; BeOne's ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeOne's ability to obtain and maintain protection of intellectual property for its medicines and technology; BeOne's reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeOne's limited experience in obtaining regulatory approvals and commercializing pharmaceutical products and its ability to obtain additional funding for operations and to complete the development of its drug candidates and maintain profitability; and those risks more fully discussed in the section entitled 'Risk Factors' in BeOne's most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeOne's subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeOne undertakes no duty to update such information unless required by law. To access BeOne media resources, please visit our Newsroom.
National Post
20 hours ago
- Business
- National Post
BeOne Medicines Receives PRIME Designation from the European Medicines Agency for BGB-16673 in Waldenstrom's Macroglobulinemia
Article content Decision highlights the promise of BGB-16673, an investigational and potentially first-in-class BTK degrader designed to overcome resistance and deepen responses in B-cell malignancies Article content SAN CARLOS, Calif. — BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Medicines Agency (EMA) has granted PRIority MEdicines (PRIME) designation to the Company's investigational Bruton's tyrosine kinase (BTK) degrader, BGB-16673, for the treatment of patients with Waldenstrom's macroglobulinemia (WM) previously treated with a BTK inhibitor. Article content 'This is the Company's first PRIME designation, marking a milestone for BeOne and providing early and enhanced interaction with the EMA as we advance BGB-16673,' said Julie Lepin, Senior Vice President, Chief Regulatory Affairs Officer at BeOne. 'PRIME allows us to align early with the EMA on key evidence requirements and potentially accelerate our path to marketing authorization of BGB-16673 for patients with relapsed or refractory Waldenstrom's macroglobulinemia.' Article content In addition to the PRIME designation, the EMA's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion on the EU Orphan Drug Designation (ODD) application for BGB-16673 in WM. A final decision is anticipated in the coming weeks. The U.S. Food and Drug Administration (FDA) also granted Fast Track Designation to BGB-16673 for the treatment of adult patients with relapsed or refractory (R/R) chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL), and adult patients with R/R mantle cell lymphoma (MCL). Article content The EMA's CHMP granted PRIME designation to BGB-16673 based on data demonstrating its novel mechanism and anti-tumor activity in B-cell malignancies. The CHMP recognized the limited treatment options available for WM patients post-BTK inhibitor therapy and acknowledged the strong biological rationale and promising clinical data for BGB-16673 in this setting, thereby demonstrating the potential to address the unmet medical need. Article content The PRIME initiative, launched by the EMA in 2016, provides early, proactive, and enhanced regulatory support to developers of promising medicines. It is designed to optimize development plans and accelerate evaluation, helping innovative therapies reach patients with unmet medical needs faster. Article content About BGB-16673 Article content BGB-16673 is an orally available Bruton's tyrosine kinase (BTK) targeting protein degrader from BeOne's chimeric degradation activation compound (CDAC) platform. BGB-16673 is designed to promote the degradation, or breakdown, of both wild-type and mutant forms of BTK, including those that commonly result in resistance to BTK inhibitors in patients who experience progressive disease. BGB-16673 is the most advanced BTK protein degrader in the clinic, with an extensive global clinical development program. Article content About BeOne Medicines Article content BeOne Medicines is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. With a growing global team of more than 11,000 colleagues spanning six continents, the Company is committed to radically improving access to medicines for far more patients who need them. To learn more about BeOne, please visit and follow us on LinkedIn, X, Facebook and Instagram. Article content Forward-Looking Statement Article content This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding BeOne's advancement of, and anticipated clinical development, regulatory milestones and commercialization of BGB-16673; the potential of BGB-16673 to significantly address the unmet medical need; and BeOne's plans, commitments, aspirations, and goals under the heading 'About BeOne.' Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeOne's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing, and progress of clinical trials and marketing approval; BeOne's ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeOne's ability to obtain and maintain protection of intellectual property for its medicines and technology; BeOne's reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeOne's limited experience in obtaining regulatory approvals and commercializing pharmaceutical products and its ability to obtain additional funding for operations and to complete the development of its drug candidates and maintain profitability; and those risks more fully discussed in the section entitled 'Risk Factors' in BeOne's most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeOne's subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeOne undertakes no duty to update such information unless required by law. Article content Article content Article content Article content Contacts Article content Investor Contact Article content Article content Liza Heapes Article content Article content +1 857-302-5663 Article content Article content ir@ Article content Media Contact Article content Article content Kyle Blankenship Article content Article content Article content
See - Sada Elbalad
a day ago
- Climate
- See - Sada Elbalad
Hot, Humid Weather Expected for Egypt on Thursday, Cairo 34°
Yara Sameh The Egyptian Meteorological Authority (EMA) predicts hot and humid weather will prevail in most of the country during Thursday's daylight hours. Extremely hot and humid weather is also expected to prevail in South Sinai and the south of the country. The weather will seem hotter due to the high humidity levels, which will push up the heat index 2-4 degrees. The country will also witness mist on agricultural and highway roads from the north of the country to Cairo. Wind will occur occasionally across the country. Light to moderate rainfall is predicted to prevail in Halayeba at intermittent periods. Light rain is also predicted to hit intermittently the North Coast and North Upper Egypt. Furthermore, maritime navigation is also expected to be disrupted in the shores of Marsa Matruh, El-Alamein, and Alexandria, with winds averaging 40 to 60 km/h and waves ranging between 2:3.5 meters. Maritime navigation will be disrupted in the Gulf of Suez, with winds averaging 40 to 55 km/h and waves ranging between 2:3 meters. Moreover, the Mediterranean Sea will experience moderate to turbulent waves ranging between 2 and 3 meters in height with northwest surface winds. Waves in the Red Sea will be moderate, ranging between 1.5 and 2 meters in height, varying between northwest and northeast surface winds. Moderately hot weather is also expected to prevail in Egypt at night and in the early hours. The predicted temperatures for the following cities are 34°C in Cairo, 31°C in Alexandria, 30°C in Marsa Matruh, 40°C in Sohag, 43°C in Qena, and 44°C in Aswan. read more Gold prices rise, 21 Karat at EGP 3685 NATO's Role in Israeli-Palestinian Conflict US Expresses 'Strong Opposition' to New Turkish Military Operation in Syria Shoukry Meets Director-General of FAO Lavrov: confrontation bet. nuclear powers must be avoided News Iran Summons French Ambassador over Foreign Minister Remarks News Aboul Gheit Condemns Israeli Escalation in West Bank News Greek PM: Athens Plays Key Role in Improving Energy Security in Region News One Person Injured in Explosion at Ukrainian Embassy in Madrid News Israeli-Linked Hadassah Clinic in Moscow Treats Wounded Iranian IRGC Fighters Arts & Culture "Jurassic World Rebirth" Gets Streaming Date News China Launches Largest Ever Aircraft Carrier News Ayat Khaddoura's Final Video Captures Bombardment of Beit Lahia Videos & Features Tragedy Overshadows MC Alger Championship Celebration: One Fan Dead, 11 Injured After Stadium Fall Business Egyptian Pound Undervalued by 30%, Says Goldman Sachs Lifestyle Get to Know 2025 Eid Al Adha Prayer Times in Egypt Arts & Culture South Korean Actress Kang Seo-ha Dies at 31 after Cancer Battle Arts & Culture Lebanese Media: Fayrouz Collapses after Death of Ziad Rahbani Sports Get to Know 2025 WWE Evolution Results
